Trials / Completed
CompletedNCT02013622
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability. Early-episode schizophrenia is defined as episodes occurring ≤ 5 years after the onset of the first episode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-09-01
- Completion
- 2014-10-01
- First posted
- 2013-12-17
- Last updated
- 2016-03-29
- Results posted
- 2016-03-29
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02013622. Inclusion in this directory is not an endorsement.